Previous 10 | Next 10 |
Few stocks with a market cap above a billion dollars display as much volatility as Cassava Sciences. Their efforts to develop a drug for Alzheimer's patients have recently been met with attacks by short-sellers alleging fraud. There are numerous ways for investors to position them...
Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire NEW YORK , Sept. 10, 2021 /PRNewswire/ -- Synaptogenix, Inc (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics...
Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome - Bryostatin-1 to benefit from previously granted Orphan Drug Status for the treatment of Fragile X syndrome...
Gainers: Tyme Technologies TYME +46%, Xenetic Biosciences XBIO +40%, IMV (IMV) +18%, Translate Bio (TBIO) +10%, Reviva Pharmaceuticals (RVPH) +9%.Losers: ATI Physical Therapy ATIP -40%, Iterum Therapeutics ITRM -36%, Intec Pharm...
Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021 - Presentation entitled: "Bryostatin Restores Cognitive Functions Above Baseline in Advanced Alzheimer's Disease (AD) Patients: A...
India Globalization Capital (IGC) +128% announces issuance of Patent for the treatment of Alzheimer’s disease using THCPainReform (PRFX) +51%.ImmunoPrecise Antibodies IPA +41% highlights new data from TATX-03 SARS-CoV-2 Delta studySequential Brands (SQBG) +28%.NeuroMetri...
Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings PR Newswire NEW YORK , July 21, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative disea...
Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline PR Newswire NEW YORK , July 14, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging bioph...
Synaptogenix ([[SNPX]] +1.7%) announces that a new patent has been awarded by the U.S. Patent and Trademark Office in relation to the treatment of Alzheimer's disease.Patent number 16/914,399 is entitled: Methods for Inducing Synaptogenesis with Synaptic Growth Factor Activating Compounds.The...
Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease PR Newswire NEW YORK , July 7, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerat...
News, Short Squeeze, Breakout and More Instantly...
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury PR Newswire Company holds exclusive rights to family of polyunsaturated fatty acid (PUFA) analogs New patent covers proprietary analogs in ...
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis PR Newswire Collaborative study will evaluate drug's potential to improve synaptic health and cognitive function in MS patients NEW YORK , ...